Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CFDA Pharmacopoeia Order Could Lead to Greater Import Testing

This article was originally published in PharmAsia News

Executive Summary

Foreign medicinal products entering China could face greater testing at customs ports and encounter potential hurdles - especially with regard to products not included in the revised Chinese Pharmacopoeia (ChP) - following the China Food and Drug Administration's recent notice reinforcing the applicability of ChP to all imported drugs.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register